Stargardt Disease Market Projected to Grow at a Significant CAGR Through 2034

The Stargardt disease market is poised for remarkable growth over the next decade, driven by an expanding pipeline of innovative therapies, increasing disease awareness, improved diagnostic capabilities, and significant research investments from key players. DelveInsight's report provides comprehensive insights into the historical and projected Stargardt disease epidemiology, treatment patterns, emerging therapies, competitive intelligence, and market trends across the 7MM, comprising the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. The Stargardt disease market size was nearly USD 30 million across 7MM in 2023, which is expected to grow at a significant CAGR through 2034.

Key Takeaways:

• The Stargardt disease market size is expected to reach USD 250 million by 2034, growing at a significant CAGR of 22.5% through 2034.
• The US currently dominates the market landscape, mainly due to a large patient pool, advanced healthcare infrastructure, and strong presence of leading pharmaceutical companies and research institutions actively developing new therapies.
• Alkeus Pharmaceuticals' gildeuretinol, Nanoscale Therapeutics' MCO-010 (Sonpiretigene Isteparvovec), and Belite Bio's Tinlarebant are among the promising therapies in the Stargardt disease pipeline, with several clinical and regulatory milestones achieved in recent years.
• The Stargardt disease pipeline has gained remarkable momentum, with several promising candidates advancing through clinical development, driven by advancements in genetic technologies like CRISPR-Cas9, which offer breakthrough potential for targeted genetic interventions.
• The Stargardt disease therapeutic landscape represents a significant unmet medical need, with no FDA-approved treatments that effectively halt or reverse vision loss, mandating the need for innovative therapeutic approaches targeting the underlying Stargardt disease mechanisms.
• The current Stargardt disease management strategies primarily focus on photoprotection through avoidance of direct sunlight, alongside recommendations against vitamin A supplementation, which may accelerate lipofuscin accumulation in patients with ABCA4-mediated disease, highlighting the need for effective disease-modifying treatments.
• MCO-010 (Sonpiretigene Isteparvovec) is expected to capture the largest market share by 2034, followed closely by ALK-001 (gildeuretinol).

Statistics:

• The Stargardt disease market size was nearly USD 30 million across 7MM in 2023, with an expected growth rate of 22.5% through 2034.
• The US dominates the market landscape, accounting for approximately 43% of the total diagnosed prevalent cases.
• The Stargardt disease patient pool is segmented into three distinct categories: early-onset ( 40 years).
• Approximately 10 to 13 per 100,000 individuals in the US are affected by Stargardt disease, accounting for the largest Stargardt disease patient pool across 7MM.

Sources:

• DelveInsight's "Stargardt Disease Market Insight, Epidemiology And Market Forecast - 2034" report
• News releases from Alkeus Pharmaceuticals, Kubota Pharmaceuticals, Nanoscope Therapeutics, Belite Bio, and Astellas Pharma
• Regulatory submissions from Ocugen and SpliceBio
• Published papers from SalioGen Therapeutics, Ascidian, Biogen, and Ascidian.